Skip to content
    Clinical Trials

    Melatonin improves sleep and fatigue in head and neck cancer, trial finds

    Pushpa et alIndian journal of cancer

    Melatonin improves sleep and fatigue in head and neck cancer, trial finds
    In a prospective, randomized, double-blind, placebo-controlled trial, researchers evaluated the therapeutic impact of oral melatonin on sleep disturbances, fatigue, and caregiver sleep perception in 70 patients aged 18 to 65 years with head and neck cancer who had experienced sleep issues for more than one month. Participants were randomized to receive either 3 mg of oral melatonin once daily (Group M, n = 35) or a multivitamin placebo (Group P, n = 35) for a duration of 14 days. Clinical outcomes were measured at baseline and on day 14 using the Pittsburgh Sleep Quality Index (PSQI), the Fatigue Assessment Scale (FAS), and caregiver perception metrics covering satisfaction, alertness, timing, efficiency, and duration. At day 14, patients treated with melatonin achieved significantly lower PSQI scores compared to the placebo group (8.11 ± 1.55 vs. 9.66 ± 1.83; P = 0.0003), with intra-group significant improvements observed exclusively in the melatonin arm (P < 0.001). Melatonin also led to significantly lower FAS fatigue scores relative to placebo (12.66 ± 2.44 vs. 14.69 ± 1.94; P = 0.0003) and yielded significant enhancements in caregiver sleep perception (P < 0.0001). The study demonstrates that short-term low-dose melatonin effectively alleviates sleep disruption and cancer-related fatigue while concurrently benefiting caregiver sleep perception.

    Key Takeaways

    • Daily administration of oral melatonin (3 mg once daily for 14 days) significantly improved sleep quality compared to placebo in patients with head and neck cancer, resulting in lower Day-14 Pittsburgh Sleep Quality Index scores (8.11 ± 1.55 vs. 9.66 ± 1.83; P = 0.0003).
    • Patients receiving oral melatonin experienced significantly reduced fatigue compared to placebo, as demonstrated by lower Day-14 Fatigue Assessment Scale scores (12.66 ± 2.44 vs. 14.69 ± 1.94; P = 0.0003).
    • Melatonin treatment was associated with a statistically significant improvement in caregiver sleep perception scores compared to placebo (P < 0.0001).
    Read the original sourceIndian journal of cancer